Case Study 3 Involving Merck S Crixivan

Question Description

Resource allocation, scarcity, pricing, and stakeholder involvement are recurring issues in healthcare. Thetreatment for HIV discussed in this case is no longer groundbreaking; the lessons remain salient. A currentexample is Gilead’s hepatitis C drug, Sovaldi, that costs $1,000 per pill, or more than $84,000 per patient in acourse of treatment. Demand for Sovaldi is high, but its cost causes access problems for many patients. Howshould a costly, scarce resource be allocated? Does Gilead have a responsibility to increase access to Sovaldi?Merck’s Crixivan offers insight into such issues.

file:///Users/pramodthomas/Downloads/20190526032135cases_in_health_service_management_.pdf